QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$39.96 USD
+0.43 (1.09%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $39.98 +0.02 (0.05%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth D Momentum D VGM
Company Summary
San Diego, CA-based QuidelOrtho Corporation (earlier known as Quidel Corporation) is a key player in the provision of in-vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine. The company sells its products directly to end users and distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent-care clinics, leading universities, retail clinics, pharmacies and wellness screening centers.
Following its combination with Ortho Clinical Diagnostics Holdings plc, QuidelOrtho reorganized its former product categories into four business units.
For the second quarter, Labs revenues were $354.2 ...
Company Summary
San Diego, CA-based QuidelOrtho Corporation (earlier known as Quidel Corporation) is a key player in the provision of in-vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine. The company sells its products directly to end users and distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent-care clinics, leading universities, retail clinics, pharmacies and wellness screening centers.
Following its combination with Ortho Clinical Diagnostics Holdings plc, QuidelOrtho reorganized its former product categories into four business units.
For the second quarter, Labs revenues were $354.2 million, down 2% and 1% on a reported basis and at CER, respectively.
Transfusion Medicine (TM) revenues were $161.3 million in the second quarter, down 1.2% on a reported basis but up 0.5% at CER.
Point-of-Care (POC) revenues amounted to $117.1 million in the second quarter, reflecting a decline of 12.7% and 12.8% on a reported basis and at CER, respectively.
Molecular Diagnostics (MDx) revenues totaled $4.4 million in the second quarter, down 29% on a reported basis and 29.4% at CER.
QuidelOrtho has also changed its reportable segments to four geographically based segments following its combination. North America (down 7.6% in the second quarter on a reported basis, down 7.7% at CER), Europe, the Middle East and Africa (EMEA) (up 0.6% reportedly, up 1% at CER), China (up 0.4% reportedly, up 4.1% at CER) and Latin America, Japan and the Asia Pacific are included in Other (down 0.2% reportedly, up 2.9% at CER).
General Information
QuidelOrtho Corporation
9975 SUMMERS RIDGE ROAD
SAN DIEGO, CA 92121
Phone: 858-552-1100
Fax: 858-453-4338
Web: http://www.quidelortho.com
Email: ir@quidelortho.com
Industry | Medical - Products |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.31 |
Current Year EPS Consensus Estimate | 1.75 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 39.53 |
52 Week High | 75.86 |
52 Week Low | 29.74 |
Beta | 0.12 |
20 Day Moving Average | 526,204.94 |
Target Price Consensus | 52.50 |
4 Week | -6.24 |
12 Week | -8.66 |
YTD | -46.36 |
4 Week | -6.75 |
12 Week | -14.17 |
YTD | -55.76 |
Shares Outstanding (millions) | 67.24 |
Market Capitalization (millions) | 2,657.81 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 22.59 |
Trailing 12 Months | 16.20 |
PEG Ratio | NA |
vs. Previous Year (Q0/Q-4) | -126.92% |
vs. Previous Quarter (Q0/Q-1) | -119.44% |
vs. Previous Year (Q0/Q-4) | -4.22% |
vs. Previous Quarter (Q0/Q-1) | -10.41% |
Price/Book | 0.84 |
Price/Cash Flow | 3.59 |
Price / Sales | 0.94 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 3.87 |
3/31/24 | 3.96 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.09 |
3/31/24 | 2.24 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.44 |
3/31/24 | 1.55 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.79 |
3/31/24 | 0.81 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 5.61 |
3/31/24 | 6.33 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -65.60 |
3/31/24 | -61.65 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -70.08 |
3/31/24 | -65.95 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 47.20 |
3/31/24 | 49.46 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.55 |
3/31/24 | 2.63 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.70 |
3/31/24 | 0.68 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 41.02 |
3/31/24 | 40.39 |